News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
The company showcased three core programs developed through this platform
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Subscribe To Our Newsletter & Stay Updated
